Esophageal Cancer, Metastatic Disease
Conditions
Brief summary
Treatment of stage IV esophageal cancer is traditionally palliative, but treatment response is usually poor. The role of surgery in the treatment of advanced esophageal cancer remains controversial. We sought to determine whether surgical treatment followed by neoadjuvant chemoradiation therapy might provide survival benefits for these patients. A retrospective review of esophageal cancer patients with M1 disease treated at National Taiwan University Hospital was performed from April 2002 to June 2021. Patient demographics and cancer staging, treatment, and disease recurrence, and time of follow up were included for analysis. Univariate and multivariate analysis was performed for overall survival and progression-free survival analysis. Propensity score matching based on patient age and tumor staging characteristics was also performed for analysis.
Interventions
None listed
Sponsors
National Taiwan University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Inclusion criteria
* Stage IV Esophageal Cancer patients * Patients were treated with chemoradiation therapy (CCRT)
Exclusion criteria
* Not Stage IV Esophageal Cancer patients * Patients were not treated with chemoradiation therapy (CCRT)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival and progression-free survival | 5 years | Overall survival (OS) and progression-free survival (PFS) curves of patients with or without esophagectomy in the entire study cohort of stage IV esophageal cancer with distant metastasis. |
Countries
Taiwan
Outcome results
None listed